Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TML-NEP-19
- Development stage
- Preclinical
- Lead developer
- Themis Medicare
- Modality
- Small Molecules
01
Overview
TML-NEP-19 is a preclinical-stage analgesic candidate developed by Themis Medicare. It is classified as an opioid and is being developed as a new dosage form, likely utilizing a novel formulation or delivery technology to improve the pharmacokinetic or safety profile of an opioid molecule. The drug is currently in the preclinical phase of development for pain management.
Beyond the preview
Go deeper on TML-NEP-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TML-NEP-19.